Customer revenue $0.4m as cash burn $5.9m leaves $2.5m on hand

The reported loss narrowed (PBT -$6.0m from -$7.5m; NPAT -$6.0m from -$8.6m, both carrying a basis-discontinuity caveat because the prior comparable was distorted by the acquisition), but the improvement is materially supported by that non-cash accounting reversal rather than by trading performance.

Operating cash outflow of $5.9m (FY22: $6.8m) was only modestly better, and year-end cash of $2.5m (FY22: $1.9m) is now smaller than the annual operating burn. Total liabilities fell 91.1% to $0.8m as the contingent consideration unwound; total assets fell 37.6% and equity 16.9%.

1. With $2.5m of cash against a $5.9m operating outflow, implied runway is under six months absent a capital raise, further cost reductions, or a step-change in cash receipts. The decision to cease manufacturing should reduce the fixed-cost base, but the magnitude and timing of those savings are not quantified in the headline release.

2. Reported earnings quality is weak. The HY23 release identified a $4.1m fair value gain on contingent consideration which produced a positive H1 NPAT of $0.7m; the second-half NPAT implied by full-year data is therefore around -$6.7m. The full-year reduction in reported loss is, in substance, an accounting reversal of an acquisition-related liability rather than an operational improvement.

3. Strategic pivot is the real story. Rua has ceased manufacturing, signed a five-year Poland supply agreement with Motagon, and was positioning for a German launch at the interim. The model is now export-led branding and distribution rather than vertical integration, and validation will depend on future commercial revenue rather than fair value movements.

The half-on-half shape of NPAT is heavily distorted by the H1 fair value gain — H1 was +$0.7m and H2 implied -$6.7m — so the second half is the cleaner read on underlying losses. Operating cash burn was more evenly distributed (H1 -$3.7m, H2 -$2.3m), suggesting some cost containment in H2 as the manufacturing wind-down progressed.

With cash at $2.5m the binding forward question is funding. Neither the headline release nor the supplied excerpts disclose a capital plan, so the result does not on its own answer how the next 12 months are funded.

Both the PBT and NPAT narrowing carry a basis-discontinuity caveat because the prior comparable included the Zalm acquisition transaction and the current period includes the reversal of related contingent-consideration accounting. Stripping out fair value gains, customer revenue ($0.4m) and operating cash outflow ($5.9m) are the cleaner indicators, and both describe a business still in early commercialisation. Capex fell to $0.1m (capex/revenue 1.1%; capex down 75% versus prior), consistent with the manufacturing exit, so the modest free-cash-flow improvement is structural rather than evidence of through-cycle earning power.

Working capital movements were minor and largely mechanical: inventory fell from $0.2m to $0.01m as manufacturing wound down, and trade receivables of $0.1m reflect the early-stage scale of customer billing. The cash position improved despite a large operating outflow, which implies a financing inflow during the year; the headline release does not break this down, so the underlying source — and any associated dilution — is not visible from the supplied excerpts.

This briefing cannot assess the funding plan, the size or phasing of post-manufacturing cost savings, or the commercial economics of the European contracts beyond what the headline release discloses.